FGF2 and ovarian carcinoma: The therapeutic potential of P7 was also tested in bFGF-stimulated SKOV3 epithelial ovarian cancer cells, whose proliferation and migration were inhibited, suggesting that the P7 peptide could be a good candidate for targeted therapy of breast and ovarian cancers [154].